American Century Companies Inc. Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)

American Century Companies Inc. increased its position in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 98.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 45,360 shares of the company’s stock after buying an additional 22,536 shares during the quarter. American Century Companies Inc.’s holdings in Cardiff Oncology were worth $101,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Callan Capital LLC boosted its stake in Cardiff Oncology by 37.2% during the first quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock worth $228,000 after buying an additional 11,600 shares during the period. Blair William & Co. IL grew its holdings in Cardiff Oncology by 32.4% during the 1st quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock worth $919,000 after acquiring an additional 42,180 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Cardiff Oncology by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after buying an additional 9,468 shares during the period. Assenagon Asset Management S.A. raised its holdings in Cardiff Oncology by 380.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after purchasing an additional 962,940 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Cardiff Oncology in the second quarter valued at approximately $256,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They issued a “buy” rating and a $8.00 target price for the company.

Cardiff Oncology Stock Up 2.8 %

Shares of CRDF opened at $2.60 on Friday. Cardiff Oncology, Inc. has a 52 week low of $0.94 and a 52 week high of $6.42. The company has a market capitalization of $116.29 million, a price-to-earnings ratio of -2.89 and a beta of 1.96. The stock’s 50-day moving average price is $2.39 and its 200-day moving average price is $3.17.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. During the same quarter in the prior year, the company posted ($0.25) EPS. As a group, equities analysts anticipate that Cardiff Oncology, Inc. will post -1 EPS for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.